Patents by Inventor Peter Casteels
Peter Casteels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230211006Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.Type: ApplicationFiled: June 27, 2022Publication date: July 6, 2023Applicant: Ablynx N.V.Inventors: Daniel Janssen, Peter Schotte, Francis Descamps, Carlo Boutton, Peter Casteels
-
Patent number: 11426468Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (1ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.Type: GrantFiled: December 18, 2015Date of Patent: August 30, 2022Assignee: Ablynx N.V.Inventors: Daniel Janssen, Peter Schotte, Francis Descamps, Carlo Boutton, Peter Casteels
-
Publication number: 20210371457Abstract: The present invention relates method for purifying antibodies, said method comprising a limited number of steps while still allowing obtaining high yields of purified antibodies with an appropriate degree of purity. Briefly, this method comprises only filtration and precipitation steps, omitting the need for chromatography steps.Type: ApplicationFiled: October 8, 2019Publication date: December 2, 2021Applicant: Ablynx N.V.Inventors: Peter Casteels, Willem Van De Velde, Anthony Van De Putte, Sindi De Vrieze
-
Publication number: 20210346287Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: ApplicationFiled: April 19, 2021Publication date: November 11, 2021Applicant: Ablynx N.V.Inventors: Erik Depla, Mauro Sergi, Peter Casteels
-
Patent number: 11021544Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.Type: GrantFiled: February 5, 2016Date of Patent: June 1, 2021Assignee: Ablynx N.V.Inventors: Carlo Boutton, Daniel Janssen, Peter Casteels, Peter Schotte, Francis Descamps
-
Patent number: 11007146Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: GrantFiled: April 24, 2017Date of Patent: May 18, 2021Assignee: Ablynx N.V.Inventors: Erik Depla, Mauro Sergi, Peter Casteels
-
Patent number: 10544211Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.Type: GrantFiled: November 14, 2016Date of Patent: January 28, 2020Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
-
Publication number: 20190100599Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.Type: ApplicationFiled: February 5, 2016Publication date: April 4, 2019Applicant: Ablynx N.V.Inventors: Carlo Boutton, Daniel Janssen, Peter Casteels, Peter Schotte, Francis Descamps
-
Publication number: 20170360955Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (1ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.Type: ApplicationFiled: December 18, 2015Publication date: December 21, 2017Applicant: ABLYNX N.V.Inventors: Daniel Janssen, Peter Schotte, Francis Descamps, Carlo Boutton, Peter Casteels
-
Publication number: 20170333344Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: ApplicationFiled: April 24, 2017Publication date: November 23, 2017Applicant: Ablynx N.V.Inventors: ERIK DEPLA, Mauro Sergi, Peter Casteels
-
Publication number: 20170267752Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.Type: ApplicationFiled: November 14, 2016Publication date: September 21, 2017Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
-
Patent number: 9745372Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.Type: GrantFiled: March 13, 2017Date of Patent: August 29, 2017Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
-
Patent number: 9713589Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: GrantFiled: February 11, 2011Date of Patent: July 25, 2017Assignee: Ablynx N.V.Inventors: Erik Depla, Mauro Sergi, Peter Casteels
-
Publication number: 20170190769Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.Type: ApplicationFiled: March 13, 2017Publication date: July 6, 2017Applicant: Ablynx N.V.Inventors: MARIE-ANGE Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
-
Publication number: 20130019860Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.Type: ApplicationFiled: February 11, 2011Publication date: January 24, 2013Applicant: Ablynx N.V.Inventors: Erik Depla, Mauro Sergi, Peter Casteels
-
Publication number: 20110091462Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.Type: ApplicationFiled: March 5, 2009Publication date: April 21, 2011Applicant: ABLYNX N.V.Inventors: Peter Casteels, Marc Jozef Lauwereys, Patrick Stanssens, Christine Labeur, Carlo Boutton, Ann Brigé, Hendricus Renerus Jacobus M Hoogenboom, Els Anna Alice Beirnaert
-
Patent number: 5466671Abstract: This invention provides a purified polypeptide having antibacterial activity comprising a first sequence Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; and a second sequence X2-Pro-X3-X4-X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence. This invention also provides a purified polypeptide having antibacterial activity comprising: a first sequence, at least seven amino acid residues are the same as Pro-Arg-Pro-Pro-His-Pro-Arg-X1, wherein X1 is Ile or Leu; a second sequence X2-Pro-X3-X4X5-Pro, wherein X2 is Arg or Lys, X3 is Thr, Gln or Arg, X4 is Tyr, Gln or Pro, and X5 is Val or Ala, the second sequence is N-terminal to the first sequence; and a third sequence comprising at least five amino acid residues, at least one-third of the residues are Pro, the third sequence is N-terminal to the second sequence.Type: GrantFiled: March 2, 1994Date of Patent: November 14, 1995Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Paul Tempst, Peter Casteels
-
Patent number: 5300629Abstract: New bactericidal and/or bacteriostatic, thermostable peptides which are isolated from hemolymph of immune honeybees and which are distinct from lysozymes, attacins, cecropins, diptericins and magainins. The peptides feature at least the 10 C-terminal amino acids of the following peptide:H.sub.2 N-Gly-Asn-Asn-Arg-Pro-X-Tyr-Ile-Pro-Gln-Pro-Arg-Pro-Pro-His-Pro-Arg-Z-OHin whichX is a valyl or isoleucyl residue andZ is a leucyl or isoleucyl residue.Type: GrantFiled: November 14, 1991Date of Patent: April 5, 1994Assignee: Plant Genetic Systems, N.V.Inventors: Peter Casteels, Paul Tempst, Frans Jacobs, Mark Vaeck